Articles
29 May 2009
Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
https://doi.org/10.4081/hmr.v1i8.273

Deferasirox (ICL670): from bench to bedside

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
247
Views
678
Downloads

Authors

DG Alberti
support@pagepress.org
This document accompanies the presentation by Dr Daniele Alberti, Clinical Program Leader, Novartis Pharma. The presentation provides an overview of the drug development process and refers, by way of illustration, to a case history of a Novartis compound currently completing clinical development.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Deferasirox (ICL670): from bench to bedside. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.273